Substance / Medication

Telotristat ethyl

Overview

Active Ingredient

telotristat ethyl

RxNorm CUI

1872441

Indications

Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Labeler: Lexicon Pharmaceuticals, Inc.Updated: 2025-10-01T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Carcinoid syndrome

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.

Hörsch Dieter, Anthony Lowell, Gross David J et al. · Neuroendocrinology · 2022

PMID: 33940581ObservationalFull text (PMC)

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.

Fust Kelly, Maschio Michael, Kohli Michele et al. · Pharmacoeconomics · 2020

PMID: 32157590Observational

Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study.

Benson Al B, Strosberg Jonathan, Joish Vijay N et al. · Pancreas · 2020

PMID: 32132510Observational

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.

Strosberg Jonathan, Joish Vijay N, Giacalone Susan et al. · Oncologist · 2019

PMID: 31189618ObservationalFull text (PMC)

Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.

Joish V N, Frech F, Lapuerta P · J Med Econ · 2018

PMID: 28959913Observational

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.

Anthony Lowell, Ervin Claire, Lapuerta Pablo et al. · Clin Ther · 2017

PMID: 29074312Observational

Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.

Kasi Pashtoon Murtaza · Pancreas · 2018

PMID: 29232344Case Report

Telotristat ethyl affects tumour-fibroblast crosstalk in small intestinal neuroendocrine tumours.

Hodgetts Harry, Martins Maria Castanho, Chen Luohai et al. · J Neuroendocrinol · 2025

PMID: 40998421OtherFull text (PMC)

Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors.

Li Daneng, Darden Christina, Osman Noran et al. · Cancer Manag Res · 2022

PMID: 36262750OtherFull text (PMC)

Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models.

Awasthi Niranjan, Darman Lily, Schwarz Margaret A et al. · J Cell Mol Med · 2024

PMID: 39223878PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Telotristat ethyl (substance)
SNOMED CT: 733879005
UMLS CUI: C4317559
RxNorm CUI: 1872441
Labeler: Lexicon Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.